Announcements Trials
Browse Landscape

Phase

Phase 1 27Phase 1/2 7Phase 2 5Phase 4 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 233Lymphoid 29Other hematologic neoplasm 25Tumor-Agnostic 5Head & Neck 2Endocrine 2CNS 2Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1

Conditions

Resectable Colon Cancer 1

Interventions

Carboplatin 10Cisplatin 7Pemetrexed 6Vincristine 5Nivolumab 5Etoposide 4Topotecan 3Specimen Handling 3Ipilimumab 3Injections 3Doxorubicin 3Talc 2Radiotherapy 2Paclitaxel 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1sintilimab 1ranpirnase 1raltitrexed 1pertuzumab 1pembrolizumab 1onartuzumab 1iniparib 1durvalumab 1dostarlimab 1crofelemer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leucovorin × Other solid neoplasm × Clear all
NCT07412613 2026-04-22

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Akeso

Phase 3 Recruiting
386 enrolled
GastrointestinalOther solid neoplasm

Resectable Colon Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡